logo image
search icon
HIV-Associated Lipodystrophy Treatment Market

HIV-Associated Lipodystrophy Treatment Market Size, Share & Trends Analysis Report by Lipodystrophy Type (Lipoatrophy and Lipoaccumulation), by Therapeutic class (Anabolism Modulators, Insulin Resistance Modulators, Mitochondrial Antioxidants (l-carnitine), and Other), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region, And By Segment Forecasts, 2023-2031.

Report ID : 2250 | Published : 2023-12-04 | Pages: 180 | Format: PDF/EXCEL

HIV-Associated Lipodystrophy Treatment Market Size is valued at USD 172.85 Mn in 2022 and is predicted to reach USD 239.62 Mn by the year 2031 at a 3.87% CAGR during the forecast period for 2023-2031.

HIV-Associated Lipodystrophy Treatment Market

HIV-associated lipodystrophy is an unfavourable side effect of antiretroviral therapy (ART). Lipodystrophy, often HIV-associated lipodystrophy, is a disease unique to HIV-positive people. Facial, gluteal, thigh, and limb subcutaneous fat all diminish. HIV-infected persons taking antiretroviral medicines have been linked to an increased risk of developing HIV-associated lipodystrophy, albeit these findings have not been replicated across the board. The face, thighs, upper arms, and lower legs are vulnerable to lipoatrophy.

Truncal lipohypertrophy, on the other hand, can cause various symptoms, including belly fat, breast enlargement, a floppy neck, and even lipomas. Facial lipoatrophy, in particular, has been related to low mood, low self-esteem, sexual dysfunction, and social isolation, which can devastatingly affect a patient's well-being and mobility and adhere to antiretroviral therapy (ART). Furthermore, the increased risk of cardiovascular disease is just one way lipodystrophy contributes to morbidity. Other ways include the development of insulin resistance, hyperlipidemia, and endothelial dysfunction. This highlights the critical nature of early diagnosis and treatment for HIV-related lipodystrophy.

However, the market growth is hampered by the lack of knowledge of the safety and health of the HIV-associated lipodystrophy treatment market and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high humidity HIV-associated lipodystrophy treatment, a lack of a solid foundation for the control programs; problems with drug availability; a lack of patient commitment to treatment; the presence of co-morbidities and opportunistic infections.

Patients may stop taking their HIV medication because they are afraid of developing lipodystrophy or because they worry that having lipodystrophy will make their HIV status clear to doctors. COVID-19 vaccinations are safe for use in HIV patients. Clinical studies of the COVID-19 vaccine were conducted on people living with HIV. The vaccinations against COVID-19 are safe, productive, and of high enough quality to be approved by the FDA. Diseases are monitored and prevented by the (CDC) reports. There is no evidence that the COVID-19 vaccination is incompatible with HIV treatment or prevention drugs.

Competitive Landscape

Some Major Key Players In The HIV-Associated Lipodystrophy Treatment Market:

  • Theratechnologies Inc.
  • GlaxoSmithKline plc
  • Novelion Therapeutics Inc.
  • AstraZeneca plc
  • AbbVie Inc.
  • Bristol-Myers Squibb
  • Amryt Pharmaceuticals, Inc.,
  • Fawn Incorporation,
  • Abbott Healthcare Solutions,
  • Lupin Pharmaceuticals, Inc.,
  • Pfizer Inc.,
  • Bayer Inc.,
  • Novartis Pharmaceuticals Corporation,
  • Galderma Laboratories, L.P.
  • Others

Market Segmentation

The HIV-Associated Lipodystrophy Treatment Market is segmented based on lipodystrophy type, therapeutic class, and distribution channel. Based on lipodystrophy type, the market is segmented into lipoatrophy and lipoaccumulation. By therapeutic class, the market is segmented into anabolism modulators, Growth hormones, anabolic steroids, insulin resistance modulators, metformin, thiazolidinediones, mitochondrial antioxidants (l-carnitine), and other miscellaneous metabolic agents. The distribution channel segment is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.

Based On The Therapeutic Class, The Growth Hormones HIV-Associated Lipodystrophy Treatment Market Segment Is Accounted As A Major Contributor To The HIV-Associated Lipodystrophy Treatment Market. 

The growth hormones HIV-associated lipodystrophy treatment is expected to lead with a significant global market share in 2022. Growth hormone's functions include affecting height and assisting in bone and muscular development. Growth hormone levels vary naturally throughout the day, seemingly in response to levels of physical exertion.

Online Pharmacy Segment To Witness Growth At A Rapid Rate.

The online pharmacy administration system is designed to remove physical constraints. It paves the way for telehealth services, allowing pharmacists to assist patients physically distant from them, facilitate remote order processing, and introduce new avenues for patient connection, especially in countries like the US, Germany, the UK, China, and India.

In The Region, The North American HIV-Associated Lipodystrophy Treatment Market Holds A Significant Revenue Share.

The North American HIV-associated lipodystrophy treatment market is expected to record the maximum market share in revenue in the near future. It can be attributed to the good terms of the insurance coverage. Insurance coverage for the treatment of HIV drug side effects such as HIV-related lipodystrophy was recently granted by both the Massachusetts House and Senate. The market for treatments for HIV-related lipodystrophy is anticipated to flourish due to the acceptance of such insurance coverage. In addition, Asia Pacific is estimated to grow rapidly in the global HIV-associated lipodystrophy treatment market because of a confluence of factors that emphasize the importance of a shift in perspective, improved access to care, and a heightened sense of patient agency. An ageing population and a growth in the prevalence of chronic diseases have raised the profile of advanced care planning in the region.

HIV-Associated Lipodystrophy Treatment Market Report Scope

Report Attribute

Specifications

Market Size Value In 2022

USD 172.85 Mn

Revenue Forecast In 2031

USD 239.62 Mn

Growth Rate CAGR

CAGR of 3.87 % from 2023 to 2031

Quantitative Units

Representation of revenue in US$ Million and CAGR from 2023 to 2031

Historic Year

2019 to 2022

Forecast Year

2023-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

by Lipodystrophy Type, by Therapeutic class, by Distribution Channels

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea

Competitive Landscape

Theratechnologies Inc., GlaxoSmithKline plc, Novelion Therapeutics Inc., AstraZeneca plc, AbbVie Inc., and Bristol-Myers Squibb, Amryt Pharmaceuticals, Inc., Fawn Incorporation, Abbott Healthcare Solutions, Lupin Pharmaceuticals, Inc., Pfizer Inc., Bayer Inc., Novartis Pharmaceuticals Corporation, Galderma Laboratories, L.P., and Others

Customization Scope

Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape.

Pricing And Available Payment Methods

Explore pricing alternatives that are customized to your particular study requirements.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global HIV-associated lipodystrophy treatment Market Snapshot

Chapter 4. Global HIV-associated lipodystrophy treatment Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: By Lipodystrophy type Estimates & Trend Analysis

5.1. By Lipodystrophy type, & Market Share, 2020 & 2031

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Lipodystrophy type:

5.2.1. Lipoatrophy

5.2.2. Lipoaccumulation

Chapter 6. Market Segmentation 2: By Therapeutic class Estimates & Trend Analysis

6.1. By Therapeutic class & Market Share, 2020 & 2031

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Therapeutic class:

6.2.1. Anabolism modulators

6.2.2. Growth hormones

6.2.3. Anabolic steroids

6.2.4. Insulin resistance modulators

6.2.5. Metformins

6.2.6. Thiazolidinediones

6.2.7. Others

6.2.8. Mitochondrial antioxidants (l-carnitine)

6.2.9. Other miscellaneous metabolic agents

Chapter 7. Market Segmentation 3: By Distribution channel Estimates & Trend Analysis

7.1. By Distribution channel & Market Share, 2020 & 2031

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Distribution channel:

7.2.1. Hospital pharmacies

7.2.2. Retail pharmacies

7.2.3. Online pharmacies

Chapter 8. HIV-associated lipodystrophy treatment Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America HIV-associated lipodystrophy treatment Market revenue (US$ Million) estimates and forecasts By Lipodystrophy type, 2019-2031

8.1.2. North America HIV-associated lipodystrophy treatment Market revenue (US$ Million) estimates and forecasts By Therapeutic class, 2019-2031

8.1.3. North America HIV-associated lipodystrophy treatment Market revenue (US$ Million) estimates and forecasts By Distribution channel, 2019-2031

8.1.4. North America HIV-associated lipodystrophy treatment Market revenue (US$ Million) estimates and forecasts by country, 2019-2031

8.2. Europe

8.2.1. Europe HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Lipodystrophy type, 2019-2031

8.2.2. Europe HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Therapeutic class, 2019-2031

8.2.3. Europe HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Distribution channel, 2019-2031

8.2.4. Europe HIV-associated lipodystrophy treatment Market revenue (US$ Million) by country, 2019-2031

8.3. Asia Pacific

8.3.1. Asia Pacific HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Lipodystrophy type, 2019-2031

8.3.2. Asia Pacific HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Therapeutic class, 2019-2031

8.3.3. Asia Pacific HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Distribution channel, 2019-2031

8.3.4. Asia Pacific HIV-associated lipodystrophy treatment Market revenue (US$ Million) by country, 2019-2031

8.4. Latin America

8.4.1. Latin America HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Lipodystrophy type, (US$ Million) 2019-2031

8.4.2. Latin America HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Therapeutic class, (US$ Million) 2019-2031

8.4.3. Latin America HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Distribution channel, (US$ Million) 2019-2031

8.4.4. Latin America HIV-associated lipodystrophy treatment Market revenue (US$ Million) by country, 2019-2031

8.5. Middle East & Africa

8.5.1. Middle East & Africa HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Lipodystrophy type, (US$ Million) 2019-2031

8.5.2. Middle East & Africa HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Therapeutic class, (US$ Million) 2019-2031

8.5.3. Middle East & Africa HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Distribution channel, (US$ Million) 2019-2031

8.5.4. Middle East & Africa HIV-associated lipodystrophy treatment Market revenue (US$ Million) by country, 2019-2031

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Theratechnologies Inc.,

9.2.2. GlaxoSmithKline plc,

9.2.3. Novelion Therapeutics Inc.,

9.2.4. AstraZeneca plc, AbbVie Inc.,

9.2.5. Bristol-Myers Squibb.

Segmentation of HIV-Associated Lipodystrophy Treatment Market-

HIV-Associated Lipodystrophy Treatment Market By lipodystrophy type:

  • Lipoatrophy
  • Lipoaccumulation

HIV-Associated Lipodystrophy Treatment Market Seg

HIV-Associated Lipodystrophy Treatment Market By therapeutic class-

  • Anabolism modulators
  • Growth hormones
  • Anabolic steroids
  • Insulin resistance modulators
  • Metformin
  • Thiazolidinediones
  • Mitochondrial antioxidants (l-carnitine)
  • Other miscellaneous metabolic agents

HIV-Associated Lipodystrophy Treatment Market By distribution channel-

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies

HIV-Associated Lipodystrophy Treatment Market By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

user icon
office icon
mail icon
call icon

This website is secure, and we do not share your personal information with any third party. Privacy Policy

Need Customization
Need specific information/chapter from the report of the custom data table, graph or complete report? Tell us more.

Frequently Asked Questions

How big is the HIV-Associated Lipodystrophy Treatment Market?

HIV-Associated Lipodystrophy Treatment Market expected to grow at a 3.87% CAGR during the forecast period for 2023-2031.

Lupin Pharmaceuticals, Inc., Pfizer Inc., Bayer Inc., Novartis Pharmaceuticals Corporation, Galderma Laboratories, L.P., and Others

Our Clients

  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo
  • client logo

Media Citations

  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo
  • media citation logo

Growth opportunities and latent adjacency in Pharmaceuticals

Select Licence Type
$4456
$7786
$10000
$1200
Get Your GTM Strategy

Navigate market entry with channel selection, launch strategy & timeline, and pricing model support.

Equip yourself with the insights needed to develop a winning go-to-market strategy

Get real-time updates and joint control over project direction with our collaborative approach